AmgenvsRoyalty Pharma

AMGN and RPRX stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$443.89

Value $239B

-3.07%
AMGN's page

Amgen (AMGN) has a market value of $239B and Royalty Pharma (RPRX) $29.5B. Over the last year, with dividends, AMGN moved +33.5% and RPRX +78.4%. The P/E is 25.5 for AMGN and 43.9 for RPRX. Dividend yield: AMGN 2.24%, RPRX 1.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$239B

    RPRX$29.5B

    AMGN is 8.1 times RPRX

  • Revenue, 12 months

    AMGN$38.9B

    RPRX$2.6B

    AMGN is 15 times RPRX

  • Net income, 12 months

    AMGN$9.4B

    RPRX$672M

    AMGN is 14 times RPRX

  • Operating margin

    AMGN32.4%

    RPRX57.1%

    24.7 points apart

  • ROIC

    AMGN16.2%

    RPRX6.3%

    9.9 points apart

  • P/E

    AMGN25.5

    RPRX43.9

    RPRX is 1.7 times AMGN

  • Dividend yield

    AMGN2.2%

    RPRX1.4%

    0.8 points apart

  • 5-year return

    AMGN+149.9%

    RPRX+82.2%

    67.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+149.9%

RPRX+82.2%

10020020222023202420252026
Returns by period
PeriodAMGNWith dividendsRPRXWith dividends
1 year since November 17, 2025+33.5%Price +29.9%+78.4%Price +75.4%
3 years since November 17, 2023+81.6%+22.0% a yearPrice +67.3%+177.4%+40.5% a yearPrice +158.2%
5 years since November 17, 2021+149.9%+20.1% a yearPrice +115.7%+82.2%+12.8% a yearPrice +61.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenRPRXRoyalty Pharma

Valuation

AMGNRPRX
Valuation
Price$443.89$68.67
Market value$239B$29.5B
Enterprise value (EV)$280B$37.6B
P/E25.543.9
P/E, 5-year median23.017.5
P/B16.73.0
EV/EBIT22.225.1
Free cash flow yield4.0%10.0%

Results and growth

AMGNRPRX
Results and growth
Revenue, 12 months$38.9B$2.6B
Net income, 12 months$9.4B$672M
Free cash flow, 12 months$9.6B$3.0B
Earnings per share, 12 months$17.25$1.53
Revenue growth, year on year10.0%5.1%
Revenue growth a year, past+7.6%over 5 years+2.3%over 5 years
EPS growth a year, past+2.9%over 5 years+6.2%over 5 years

Margins and returns on capital

AMGNRPRX
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%57.1%
Net margin24.1%25.7%
ROIC16.2%6.3%
ROE87.8%6.9%

Balance sheet

AMGNRPRX
Balance sheet
Cash$13.2B$545M
Total debt$54.0B$8.6B
Net debt / EBITDA2.35.4
Interest cover4.8×4.0×

Dividends and buybacks

AMGNRPRX
Dividends and buybacks
Dividend yield2.2%1.4%
Dividend per share, 12 months$9.94$0.94
Dividend growth a year, past+8.1%over 5 years–
Buyback yield–4.2%
Shareholder yield2.2%5.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or RPRX

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Royalty Pharma?

By market value, Amgen ($239B) is about 8.1 times Royalty Pharma ($29.5B), at today's prices.

How did AMGN and RPRX stock do over the last 5 years?

Since November 17, 2021, AMGN's price moved +115.7% and RPRX's +61.7%. With dividends: AMGN +149.9% (+20.1% a year), RPRX +82.2% (+12.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or RPRX?

The dividend yield at today's price is 2.24% for Amgen and 1.37% for Royalty Pharma. Over the last twelve months they paid $9.94 and $0.94 per share.

What is the P/E of AMGN and RPRX?

At today's price, the P/E is 25.5 for AMGN and 43.9 for RPRX. The median of the last five years was 23.0 and 17.5, which shows where each stands against its own past.

Which has the higher profit margins, Amgen or Royalty Pharma?

Over the last twelve months, the net margin was 24.1% for Amgen and 25.7% for Royalty Pharma, and the operating margin 32.4% and 57.1%. Revenue was $38.9B and $2.6B.

Which is the better investment, Amgen or Royalty Pharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.